Z53 Therapeutics

Z53 Therapeutics is an Australian biotechnology company dedicated to developing novel small molecule therapies that restore the function of mutant p53, a protein often referred to as the guardian of the genome. By reactivating the tumor-suppressive properties of p53, the company aims to trigger apoptosis in cancer cells across a wide range of solid tumors. The company's lead programs are designed to address the high prevalence of p53 mutations in cancers such as ovarian and breast cancer, where current treatment options are often limited. Founded on research from the University of Adelaide, Z53 Therapeutics is backed by Brandon Capital and is currently advancing its candidates through pre-clinical development toward human clinical trials.